Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Split-face, Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction

NCT06161246 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT06161246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06161246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Split-face, Controlled Study on Pain Management With Injection of Botulinum Toxin for Glabellar Line Correction
Lead sponsor
Galderma R&D
Phase
Phase 4
Overall status
Completed
Start date
October 23, 2023
Completion date
February 15, 2024
Enrollment
60 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

injection site discomfort